In consideration of the IFRS 15 “Revenues”, which is mandatory from the financial year 2018, HAEMATO AG generated IFRS Group sales of EUR 274.1 million, an operating result (EBIT) of EUR 8.5 million and a net income of EUR 6.3 million.
In the second half of 2018, as a result of the product range streamlining by eliminating low-margin products as well as the expiring patents on a number of high-revenue original preparations, HAEMATO did not achieve to continue the success of the second half of 2017 being the highest-revenue second half-year in the company‘s history. Nevertheless, in the financial year 2018, HAEMATO was able to improve the cost-of-sales by almost 1% compared to the previous year.
The capital increase of EUR 5.2 million carried out in the financial year 2018 in order to repay participation certificates improved the equity ratio from 57.2% (2017) to 65.0% in 2018 and helped, amongst others, to significantly reduce the total financial liabilities by EUR 10.9 million. For the purpose of repayment in the form of HAEMATO AG shares, 887,154 no-par-value bearer shares were issued as part of a conditional capital increase.
Being one of the leading 8 players in the parallel import business in the German pharmaceutical market, we were able to increase our market share in Germany from 3.38% in 2017 to 4.02% in 2018 according to the IQVIA market figures.
Read the complete Annual Report 2018 here: Annual Report 2018